Badania kliniczne, które rekrutują lub wkrótce zaczną rekrutację w ośrodkach w mieście Gdańsk. Najwięcej badań dotyczy: rak płuca, chłoniak, białaczka, szpiczak.
533 badania: 492 rekrutują, 41 wkrótce zacznie.
Phase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular Carcinoma
+12An Open-Label Study of Azetukalner in Major Depressive Disorder
Study of Treatment With Intensified Omeprazole Treatment to Prevent High Output Stoma 1
REVEAL: A Phase 3 Study of Obudanersen (ION582) in Angelman Syndrome
+7Ravulizumab Treatment Outcomes in Patients With Generalized Myasthenia Gravis
A Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide
A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With…
+1A Clinical Study to Investigate the Efficacy and Safety of an Investigational Combination Therapy With BNT324 and BNT327 in Patients With Advanced Lung Cancer
+3Long-term Safety Outcomes in Patients Treated With Replimune Oncolytic Immunotherapy Products
A Study to Assess the Efficacy and Safety of ML-007C-MA for the Treatment of Alzheimer's Disease Psychosis
+8Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)
+11A Study of 2 Doses of Ritlecitinib in People 12 Years of Age and Older With Alopecia Areata
+4A Double-blind Study Evaluating the Efficacy, Safety, and Tolerability of Zorevunersen in Patients With Dravet Syndrome
+2The use of dupilumab in treatment of indolent systemic mastocytosis with skin involvement
A Clinical Study of Ifinatamab Deruxtecan Based Treatment Combinations or as Monotherapy to Treat Metastatic Castrate Resistant Prostate Cancer (mCRPC)…
+11Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib
+15A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)
+17Tacrolimus and Risk Factors for Glucose Metabolism Disorders in Kidney Transplant Patients
Evaluation of Efficacy and Safety of Milsaperidone as Adjunctive Therapy in Patients With Major Depressive Disorder
Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Ravulizumab Administered Intravenously in Adult Participants at High Risk…
+10Functional and Performance Determinants in Climbers: Examining the Role of Mobility, Stability, and Fatigue Across Proficiency Levels
Application of Elbow Manipulation in Archers
A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent…
+21Comparison of inclisiran or alirocumab to standard therapy in pediatric heterozygous familial hypercholesterolemia (HeFH) – the head-to-head PICOLO-FH clinical trial
Home Monitoring of Complete Blood Count Performed by Patients - a Pilot Study on the Implementation Process in South Baltic Countries.
A Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Children (6 to < 12 Years Old) With Nonsegmental Vitiligo
+6A Study of NTRX-07 in Participants With Alzheimer's Disease
Clinical study to evaluate the safety of investigational medicinal product called AD-O51.4 in patients with advanced malignancies
A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder
+1A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously…
+20Zadzwoń i porozmawiaj z doradcą ds. badań klinicznych. Sprawdzimy w rejestrach, do których badań możesz się kwalifikować.
Nie udzielamy porad ani konsultacji medycznych. Pomagamy znaleźć badanie i skontaktować się z ośrodkiem.
Informacje pochodzą z publicznych rejestrów badań klinicznych (CTIS - Unia Europejska, ClinicalTrials.gov - USA) i są aktualizowane codziennie. Mogą różnić się od aktualnego stanu w ośrodku. Ostateczną kwalifikację do badania zawsze przeprowadza lekarz w ośrodku badawczym. Stan na 2 października 2026.